{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:33:20Z","timestamp":1789788800923,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10875-021-01195-0","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:03:57Z","timestamp":1642464237000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cocktails of KLK5 Protease Inhibitors and Anti-TNF\u03b1 Therapeutics: an Effective Treatment for Netherton Syndrome"],"prefix":"10.1007","volume":"42","author":[{"given":"Eleni","family":"Zingkou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Pampalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0747-4914","authenticated-orcid":false,"given":"Georgia","family":"Sotiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"1195_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/75977","volume":"25","author":"S Chavanas","year":"2000","unstructured":"Chavanas S, Bodemer C, Rochat A, Hamel-Teilac D, Ali M, Irvine AD, Bonaf\u00e9 JL, Wilkinson J, Ta\u00efeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25:141\u20132.","journal-title":"Nat Genet."},{"key":"1195_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/hmg\/ddi030","volume":"14","author":"DR Hewett","year":"2005","unstructured":"Hewett DR, Simons AL, Mangan NE, Jolin HE, Green SM, Fallon PG, McKenzie AN. Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum Mol Genet. 2005;14:335\u20136.","journal-title":"Hum Mol Genet"},{"key":"1195_CR3","doi-asserted-by":"publisher","first-page":"165520","DOI":"10.1016\/j.bbadis.2019.07.014","volume":"1865","author":"G Pampalakis","year":"2019","unstructured":"Pampalakis G, Zingkou E, Kaklamanis L, Spella M, Stathopoulos GT, Sotiropoulou G. Elimination of KLK5 inhibits early skin tumorigenesis by reducing epidermal proteolysis and reinforcing epidermal microstructure. Biochim Biophys Acta Mol Basis Dis. 2019;1865:165520.","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"1195_CR4","doi-asserted-by":"publisher","first-page":"e1005389","DOI":"10.1371\/journal.pgen.1005389","volume":"21","author":"L Furio","year":"2015","unstructured":"Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A. KLK5 inactivation reverses cutaneous hallmarks of Netherton syndrome. PLoS Genet. 2015;21:e1005389.","journal-title":"PLoS Genet."},{"key":"1195_CR5","doi-asserted-by":"publisher","first-page":"e1006566","DOI":"10.1371\/journal.pgen.1006566","volume":"13","author":"P Kasparek","year":"2017","unstructured":"Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R. (2017) KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype. PLoS Genet. 2017;13:e1006566.","journal-title":"PLoS Genet."},{"key":"1195_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bmcl.2019.04.022","volume":"29","author":"AL Walker","year":"2019","unstructured":"Walker AL, Bingham R, Edgar EV, Ferrie A, Holmes DS, Liddle J, Polyakova O, Rella M, Smith KJ, Thorpe JH, Wang Y, White GV, Young RJ, Hovnanian A. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. Bioorg Med Chem Lett. 2019;29:1454\u20138.","journal-title":"Bioorg Med Chem Lett."},{"key":"1195_CR7","doi-asserted-by":"publisher","unstructured":"Liddle J, Beneton V, Benson M, Bingham R, Bouillot A, Boullay AB, Brook E, Cryan J, Denis A, Edgar E, Ferrie A, Fouchet MH, Grillot D, Holmes DS, Howes A, Krysa G, Larose A, Lennon M, McClure F, Moquette A, Nicodeme E, Santiago B, Santos L, Smith KJ, Thorpe JH, Thripp G, Trottet L, Walker AL, Ward SA, Wang Y, Wilson S, Pearce AC, Hovnanian A. A potent and selective kallikrein-5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome. J Invest Dermatol 2021; https:\/\/doi.org\/10.1016\/j.jid.2021.01.029","DOI":"10.1016\/j.jid.2021.01.029"},{"key":"1195_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","volume":"184","author":"M Pasparakis","year":"1996","unstructured":"Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397\u2013411.","journal-title":"J Exp Med."},{"key":"1195_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0014-5793(98)01036-9","volume":"435","author":"A Lourbakosa","year":"1998","unstructured":"Lourbakosa A, Chinnia C, Thompsonb P, Potempac J, Travisd J, Mackiee EJ, Pike RN. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Letters. 1998;435:45\u20138.","journal-title":"FEBS Letters"},{"key":"1195_CR10","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/jid.2011.124","volume":"131","author":"L Fontao","year":"2011","unstructured":"Fontao L, Laffitte E, Briot A, Kaya G, Roux-Lombard P, Fraitag S, Hovnanian A, Saurat JH. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131:1947\u201350.","journal-title":"J Invest Dermatol."},{"key":"1195_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jdcr.2017.07.019","volume":"3","author":"\u00c2 Roda","year":"2017","unstructured":"Roda \u00c2, Mendon\u00e7a-Sanches M, Travassos AR, Soares-de-Almeida L, Metze D. Infliximab therapy for Netherton syndrome: a case report. JAAD Case rep. 2017;3:550\u20132.","journal-title":"JAAD Case rep."},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/pde.14590","volume":"38","author":"F Cicek","year":"2021","unstructured":"Cicek F, Cecik S, Kilic SS. Infliximab therapy in an infant with Netherton syndrome. Pediatr Dermatol. 2021;38:714\u20136.","journal-title":"Pediatr Dermatol."},{"key":"1195_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/21678707.2020.1857724","volume":"8","author":"E Petrova","year":"2020","unstructured":"Petrova E, Hovnanian A. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opin Orphan Drugs. 2020;8:455\u201387.","journal-title":"Expert Opin Orphan Drugs."},{"key":"1195_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","volume":"6","author":"SK Blanchard","year":"2020","unstructured":"Blanchard SK, Prose NS. Successful use of secukinumab in Netherton syndrome. JAAD Case Rep. 2020;6:577\u20138.","journal-title":"JAAD Case Rep."},{"key":"1195_CR15","first-page":"907","volume":"156","author":"I Luchsinger","year":"2020","unstructured":"Luchsinger I, Kn\u00f6pfel N, Theiler M, des Claustres MB, Barbieux C, Schwieger-Briel A, Brunner C, Donghi D, Buettcher M, Meier-Schiesser B, Hovnanian A, Weibel L. Secukinumab therapy for Netherton syndrome. JAMA. Dermatology. 2020;156:907\u201311.","journal-title":"Dermatology."},{"key":"1195_CR16","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.celrep.2020.02.021","volume":"30","author":"MR Williams","year":"2020","unstructured":"Williams MR, Cau L, Wang Y, Kaul D, Sanford JA, Zaramela LS, Khalil S, Butcher AM, Zengler K, Horswill AR, Dupont CL, Hovnanian A, Gallo RL. Interplay of staphylococcal and host proteases promotes skin barrier disruption in Netherton syndrome. Cell Rep. 2020;30:2923\u201333.","journal-title":"Cell Rep."},{"key":"1195_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jid.2016.10.008","volume":"137","author":"MR Williams","year":"2017","unstructured":"Williams MR, Nakatsuji T, Sanford JA, Vrbanac AF, Gallo RL. Staphylococcus aureus induces increased serine protease activity in keratinocytes. J Invest Dermatol. 2017;137:377\u201384.","journal-title":"J Invest Dermatol."},{"key":"1195_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","volume":"5","author":"T Ali","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79\u201399.","journal-title":"Drug Healthc Patient Saf."},{"key":"1195_CR19","doi-asserted-by":"publisher","first-page":"165831","DOI":"10.1016\/j.bbadis.2020.165831","volume":"1866","author":"E Zingkou","year":"2020","unstructured":"Zingkou E, Pampalakis G, Sotiropoulou G. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165831.","journal-title":"Biochim Biophys Acta Mol Basis Dis."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-021-01195-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T04:21:20Z","timestamp":1650428480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-021-01195-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s10875-021-01195-0","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments with animals were carried out in accordance with the EU and national legal and ethical regulations following governmental approval of the experimental protocol (Veterinary Department of Regional Units of Achaia, Region of Western Greece).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have approved the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}